Catalyst Biosciences appoints Jeanne Jew to Board of Directors, increasing board size to eight

GYRE THERAPEUTICS, INC.

Jeanne Y. Jew appointed as Class III director effective September 9, 2021, term expiring at 2024 annual meeting.
Board increased from seven to eight members in connection with the appointment.
Ms. Jew is Chief Business Officer of ALX Oncology since August 2020, with over 25 years of corporate development experience.
She will receive standard non-employee director cash and equity compensation and enter an indemnification agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeanne Y. Jew

Class III director

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2021-09-09
Filed: September 8, 2021, 7:59 PM ET

On September 8, 2021, Catalyst Biosciences, Inc. (“Catalyst”) announced that the Board of Directors of Catalyst (the “Board”), has appointed, effective as of September 9, 2021 (the “Effective Date”), Ms. Jeanne Y. Jew as a Class III director of Catalyst with a term to expire at the 2024 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeanne Y. Jew was appointed as Class III director at GYRE THERAPEUTICS, INC..

Action: appointed
Role: Class III director

Exact text from the filing

On September 8, 2021, Catalyst Biosciences, Inc. (“Catalyst”) announced that the Board of Directors of Catalyst (the “Board”), has appointed, effective as of September 9, 2021 (the “Effective Date”), Ms. Jeanne Y. Jew as a Class III director of Catalyst with a term to expire at the 2024 Annual Meeting of Stockholders.

View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-267331

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.